" class="no-js "lang="en-US"> Alex Perry - Medtech Alert
Thursday, October 09, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Alex Perry

Alex Perry

About Alex Perry

Chief Executive Officer with demonstrated history of performance transformation in the insurance and health care industries. Skilled in Strategy Development and Implementation, Performance Improvement, Team Development and People Leadership, Customer Service Transformation, Proposition Development, Risk and Control Management, Organizational Design, Business Transformation, and Management. Graduated with distinctIon from INSEAD, with a degree from Oxford University.

Related Story

Industry News

 Bupa UK Insurance Agrees New Three-year Contract with Circle Health Group

Bupa UK Insurance Agrees New Three-year Contract with Circle Health Group, Owner of BMI

September 3 2021

Bupa UK Insurance, the leading private healthcare insurance provider and Circle Health Group, Britain’s largest […]